These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 6137601)

  • 41. Decreased myo-inositol content and Na+-K+-ATPase activity in superior cervical ganglion of STZ-diabetic rat and prevention by aldose reductase inhibition.
    Greene DA; Mackway AM
    Diabetes; 1986 Oct; 35(10):1106-8. PubMed ID: 3019804
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus.
    Roy TM; Broadstone VL; Peterson HR; Snider HL; Cyrus J; Fell R; Rothchild AH; Samols E; Pfeifer MA
    Diabetes Res Clin Pract; 1990; 10(1):91-7. PubMed ID: 2123430
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of an aldose reductase inhibiting agent on limited joint mobility in diabetic patients.
    Eaton RP; Sibbitt WL; Harsh A
    JAMA; 1985 Mar; 253(10):1437-40. PubMed ID: 3918180
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The pathology of diabetic neuropathy and the effects of aldose reductase inhibitors.
    Gillon KR; King RH; Thomas PK
    Clin Endocrinol Metab; 1986 Nov; 15(4):837-53. PubMed ID: 3096616
    [No Abstract]   [Full Text] [Related]  

  • 46. Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats.
    Schmidt RE; Plurad SB; Sherman WR; Williamson JR; Tilton RG
    Diabetes; 1989 May; 38(5):569-79. PubMed ID: 2497038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.
    Tomlinson DR; Moriarty RJ; Mayer JH
    Diabetes; 1984 May; 33(5):470-6. PubMed ID: 6202576
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medical therapy in the prevention of cataract.
    Brown NA; Bron AJ
    Trans Ophthalmol Soc U K (1962); 1985; 104 ( Pt 7)():748-54. PubMed ID: 3938085
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment.
    Guy RJ; Gilbey SG; Sheehy M; Asselman P; Watkins PJ
    Diabetologia; 1988 Apr; 31(4):214-20. PubMed ID: 3290018
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy.
    Lehtinen JM; Hyvönen SK; Uusitupa M; Puhakainen E; Halonen T; Kilpeläinen H
    J Neurol; 1986 Jun; 233(3):174-7. PubMed ID: 3522813
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Review of myo-inositol and sorbinil studies.
    Clements RS
    Clin Physiol; 1985; 5 Suppl 5():90-3. PubMed ID: 3938689
    [No Abstract]   [Full Text] [Related]  

  • 52. Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase.
    Price SA; Agthong S; Middlemas AB; Tomlinson DR
    Diabetes; 2004 Jul; 53(7):1851-6. PubMed ID: 15220210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Role of aldose reductase inhibitors in the development of peripheral neuropathy in experimental diabetes].
    Kuchmerovskaia TM; Donchenko GV; Klimenko AP; Chichkovskaia GV; Pakirbaeva LV; Kozitskiĭ ZIa; Efimov AS
    Ukr Biokhim Zh (1978); 1997; 69(3):77-82. PubMed ID: 9505366
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs.
    Engerman RL; Kern TS; Larson ME
    Diabetologia; 1994 Feb; 37(2):141-4. PubMed ID: 8163047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aldose reductase inhibitors: the end of an era or the need for different trial designs?
    Pfeifer MA; Schumer MP; Gelber DA
    Diabetes; 1997 Sep; 46 Suppl 2():S82-9. PubMed ID: 9285505
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.
    van Gerven JM; Tjon-A-Tsien AM
    Drugs Aging; 1995 Jan; 6(1):9-28. PubMed ID: 7696781
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group.
    Arch Ophthalmol; 1990 Sep; 108(9):1234-44. PubMed ID: 2119168
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural-functional interactions in the therapeutic response of diabetic neuropathy.
    Sima AA; Greene DA
    Diabet Med; 1993; 10 Suppl 2():33S-34S. PubMed ID: 8334838
    [No Abstract]   [Full Text] [Related]  

  • 59. A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group.
    Macleod AF; Boulton AJ; Owens DR; Van Rooy P; Van Gerven JM; Macrury S; Scarpello JH; Segers O; Heller SR; Van Der Veen EA
    Diabete Metab; 1992; 18(1):14-20. PubMed ID: 1563531
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
    Bril V; Buchanan RA
    Diabetes Care; 2006 Jan; 29(1):68-72. PubMed ID: 16373898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.